Research Article| Volume 398, P107-116, March 15, 2019

Amyloid PET pattern with dementia and amyloid angiopathy in Taiwan familial AD with D678H APP mutation

Published:January 03, 2019DOI:


      • The study evaluated the amyloid patterns and clinical features in the Taiwan familial AD with D678H APP mutation.
      • Early onset of memory impairment and cerebral amyloid angiopathy in 2 patients.
      • The highest stardand uptake value ratio in the occipital and cerebellar cortical areas in the gCD patients.
      • The familial D678H gene mutation patients have a more potent amyloid burden than the sporadic AD patients



      The novel D678H amyloid precursor protein (APP) gene mutation has been called the “Taiwan mutation”. The study aims to identify amyloid deposition patterns and clinical features associated with this mutation.


      we analyzed the clinical manifestations, brain neuroimages and 18F-AV-45 positron emission tomography (PET) findings in symptomatic patients and asymptomatic subjects with the autosomal-dominant Alzheimer's disease (AD). We compared the amyloid deposition pattern among 10 patients with genetically-positive familial cognitive decline (CD), 18 patients with sporadic CD, and 19 healthy controls.


      The clinical features were the early onset of memory impairment in all 10 patients and cerebral amyloid angiopathy in 3 patients. The characteristic results of brain 18F-AV-45 PET included the highest standard uptake value ratio (SUVR) in the occipital and cerebellar cortical areas in the genetically-positive CD patients. In subgroup analysis, the familial AD patients had a decreased amyloid SUVR trend in most areas except for cerebellar cortex compared to those with familial mild cognitive impairment.


      Our data indicate that the familial D678H gene mutation have resulted in a more potent amyloid burden than in the patients with sporadic AD patients. The high amyloid uptake in the occipital area is characteristic of the specific Taiwan APP gene.


      ADAS-Cog (Alzheimer's disease assessment scale-cognitive subscale), AD (Alzheimer's disease), (amyloid-β), APP (amyloid precursor protein), APoE (apolipoprotein), CD (cognitive decline), FAD (familial Alzheimer's disease), FLAIR (fluid attenuation inversion recovery), gAD (genetic Alzheimer's disease), gCD (genetic cognitive decline), HC (healthy control), MCI (mild cognitive impairment), MMSE (Mini-Mental State Examination), PCR (polymerase chain reaction), PS1 (presenilin 1), PS2 (presenilin 2), sAD (sporadic Alzheimer's disease), sCD (sporadic cognitive decline), SUVR (standard uptake value ratio), VOI (volume of interest)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hardy J.A.
        • Selkoe D.J.
        The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
        Science. 2002; 297: 353-356
        • Rosenberg R.N.
        The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture.
        Neurology. 2000; 54: 2045-2054
        • Tanzi R.E.
        A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders.
        J. Clin. Invest. 1999; 104: 1175-1179
        • Mullan M.
        • Crawford F.
        • Axelman K.
        • Houlden H.
        • Lilius L.
        • Winblad B.
        • Lannfelt L.
        A pathogenic mutation for probable Alzheimer's disease in APP gene at the N-terminus of beta amyloid.
        Nat. Genet. 1992; 1: 345-347
        • St George-Hyslop P.H.
        • Tanzi R.E.
        • Polinski P.J.
        • Haines J.L.
        • Nee L.
        • Watkins P.C.
        • et L.
        The genetic defect causing familial Alzheimer's disease maps on chromosome 21.
        Science. 1987; 235: 885-890
        • Lee M.K.
        • Borchelt D.R.
        • Kim G.
        • Gopal Thinakaran
        • Slunt H.H.
        • Tamara Ratovitski
        • et al.
        Hyperaccumulation of FAD-linked presenilin 1 variants in vivo.
        Nat. Med. 1997; 3: 756-759
        • Sherrington R.
        • Rogaev E.I.
        • Liang Y.
        • Rogaeva E.A.
        • Levesque G.
        • Ikeda M.
        • et al.
        Cloning of a gene bearing missense mutation in early onset familial Alzheimer's disease.
        Nature. 1995; 375: 754-760
        • Goate A.
        • Chartier-Harlin M.C.
        • Mullan M.
        • Brown J.
        • Crawford F.
        • Fidani L.
        • et al.
        Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.
        Nature. 1991; 349: 704-706
        • Haan J.
        • Hardy J.A.
        • Roos R.A.
        Hereditary cerebral hemorrhage with amyloidosis-Dutch type: its importance for Alzheimer research.
        Trends Neurosci. 1991; 14: 231-234
        • Zhou L.
        • Brouwers N.
        • Benilova I.
        • Vandersteen A.
        • Mercken M.
        • Van Laere K.
        • et al.
        Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β'-site increases Aβ generation.
        EMBO Mol. Med. 2011; 3: 291-302
        • Carter D.A.
        • Desmarais E.
        • Bellis M.
        • Campion D.
        • Clerget-Darpoux F.
        • Brice A.
        • et al.
        More missense in amyloid gene.
        Nat. Genet. 1992; 2: 255-256
        • Armstrong J.
        • Boada M.
        • Rey M.J.
        • Vidal N.
        • Ferrer I.
        Familial Alzheimer disease associated with A713T mutation in APP.
        Neurosci. Lett. 2004; 11: 241-243
        • Hendriks L.
        • van Duign C.M.
        • Cras P.
        • Cruts M.
        • Van Hul W.
        • van Harskamp F.
        Presenile dementia and cerebral hemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene.
        Nat. Genet. 1992; 1: 218-221
        • Grabowski T.J.
        • Cho H.S.
        • Vonsattel J.P.
        • Rebeck G.W.
        • Greenberg S.M.
        Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy.
        Ann. Neurol. 2001; 49: 697-705
        • Di Fede G.
        • Catania M.
        • Morbin M.
        • Rossi G.
        • Suardi S.
        • Mazzoleni G.
        • et al.
        A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis.
        Science. 2009; 323: 1473-1477
        • Sleegers K.
        • Brouwers N.
        • Gijselinck I.
        • Theuns J.
        • Goossens D.
        • Wauters J.
        • et al.
        APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy.
        Brain. 2006; 129: 2977-2983
        • Chen W.T.
        • Hong C.J.
        • Lin Y.T.
        • Chang W.H.
        • Huang H.T.
        • Liao J.Y.
        • et al.
        Amyloid-beta (Aβ) D7H mutation increases oligomeric Aβ42 and alters properties of Aβ-Zinc/copper assemblies.
        PLoS One. 2012; 7: e34666
        • Lan M.Y.
        • Liu J.S.
        • Wu Y.S.
        • Peng C.H.
        • Chang Y.Y.
        A novel APP mutation (D678H) in a Taiwanese patient exhibiting dementia and cerebral microvasculopathy.
        J. Clin. Neurosci. 2013; 21: 513-515
      1. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. 2009; Brain 132: 1355–65.

        • Jack C.R.
        • Knopman D.S.
        • Jagust W.J.
        • Shaw L.M.
        • Aisen P.S.
        • Weiner M.W.
        • et al.
        Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
        Lancet Neurol. 2010; 9: 119-128
        • Clark C.M.
        • Schneider J.A.
        • Bedell B.J.
        • Beach T.G.
        • Bilker W.B.
        • Mintun M.A.
        • et al.
        Use of florbetapir PET for imaging beta-amyloid pathology.
        JAMA. 2011; 305: 275-283
        • Huang K.L.
        • Lin K.J.
        • Hsiao I.T.
        • Kuo H.C.
        • Hsu W.C.
        • Chuang W.L.
        • et al.
        Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by 18F-AV-45 positron emission tomography in Chinese population.
        PLoS One. 2013; 8: e58974
      2. Mckhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on aging and the Alzheimer's association workgroup. Alzheimers Dement. 2011; 7: 263–9.

        • Wang P.N.
        • Hong C.J.
        • Lin K.N.
        • Liu H.C.
        • Chen W.T.
        APOE episilon 4 increase the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan.
        J. Neurol. Neurosurg. Psychiatry. 2011; 82: 165-169
        • Ryan N.S.
        • Nicholas J.M.
        • Weston P.S.
        • Liang Y.
        • Lashley T.
        • Guerreiro R.
        • et al.
        Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.
        Lancet Neurol. 2016; 15: 1326-1335
        • Yao C.H.
        • Lin K.J.
        • Weng C.C.
        • Hsiao I.T.
        • Ting Y.S.
        • Yen T.C.
        • et al.
        GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.
        Appl. Radiat. Isot. 2010; 68: 2293-2297
        • Lin K.J.
        • Hsu W.C.
        • Hsiao I.T.
        • Wey S.P.
        • Jin L.W.
        • Skovronsky D.
        • et al.
        Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.
        Nucl. Med. Biol. 2010; 37: 497-508
        • Wu K.Y.
        • Liu C.Y.
        • Chen C.S.
        • Chen C.H.
        • Hsiao I.T.
        • Hsieh C.J.
        • et al.
        Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: F-florbetapir (AV-45/Amyvid) PET study.
        Eur. J. Nucl. Med. Mol. Imaging. 2016; 43: 1067-1076
        • Sevigny J.
        • Chiao P.
        • Bussière T.
        • Weinreb P.H.
        • Willians L.
        • Maier M.
        • et al.
        The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
        Nature. 2016; 537: 50-56
        • Wakutani Y.
        • Watanabe K.
        • Adachi Y.
        • Wada-Isoe K.
        • Urakami K.
        • Ninomiya H.
        • et al.
        Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease.
        J. Neurol. Neurosurg. Psychiatry. 2004; 75: 1039-1042
        • Ono K.
        • Condron M.M.
        • Teplow D.B.
        Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity.
        J. Biol. Chem. 2010; 285: 23186-23197
        • Lin Y.C.
        • Wang J.Y.
        • Wang K.C.
        • Liao J.Y.
        • Cheng I.H.
        Differential regulation of amyloid precursor protein sorting with pathological mutations results in a distinct effect on amyloid-β production.
        J. Neurochem. 2014; 131: 407-412
        • Duce J.A.
        • Bush A.I.
        Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics.
        Prog Neuobiol. 2010; 92: 1-18
        • Benson D.F.
        • Davis R.J.
        • Snyder B.D.
        Posterior cortical atrophy.
        Arch Neural. 1988; 45: 789-793
        • Rabinovici G.D.
        • Furst A.J.
        • Alkalay A.
        • Racine C.A.
        • O'Neil J.P.
        • Janabi M.
        • et al.
        Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.
        Brain. 2010; 133: 512-528
        • Johnson K.A.
        • Gregas M.
        • Becker J.A.
        • Catherine Kinnecom
        • Salat D.H.
        • Moran E.K.
        • et al.
        Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.
        Ann. Neurol. 2007; 62: 229-234
        • Rosand J.
        • Muzikansky A.
        • Kumar A.
        • Wisco J.J.
        • Smith E.E.
        • Betensky R.A.
        • et al.
        Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy.
        Ann. Neurol. 2005; 58: 459-462